Patents by Inventor Clark Bennett
Clark Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090155390Abstract: A composition for treating permanent and temporary hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal.Type: ApplicationFiled: November 21, 2008Publication date: June 18, 2009Inventors: Josef M. Miller, Colleen G. Le Prell, D. Clark Bennett, Peter A. Boxer
-
Patent number: 7264799Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.Type: GrantFiled: February 22, 2006Date of Patent: September 4, 2007Assignee: BioMarin Pharmaceutical Inc.Inventors: D. Clark Bennett, Elizabeth Cauchon, Dominique Fink, Brigette Grouix, Ariane Hsia, Pamela Danagher, Joseph F. Zimmermann
-
Publication number: 20010006635Abstract: Heparinase enzymes can be used as a medical treatment to reduce localized inflammatory responses. Treatment of activated endothelium with heparinase inhibits leukocyte rolling, adhesion and extravasation. Most of the heparin and heparan sulfate on endothelial cell surfaces and in basement membranes is degraded by exposure to heparinase. In addition, immobilized chemokines, which are attached to heparin/heparan sulfate on activated endothelium are solubilized by heparinase digestion. Heparinase can be infused into the vascular system to inhibit accumulation of leukocytes in inflamed tissue and decrease damage resulting from localized inflammations. Targeting of heparinase to activated endothelium can be accomplished through localized administration and/or use of genetically engineered heparinase containing endothelium ligand-binding domains.Type: ApplicationFiled: September 27, 1996Publication date: July 5, 2001Inventors: D. CLARK BENNETT, ELIZABETH CAUCHON, DOMINIQUE FINK, BRIGETTE GROUIX, ARIANE HSIA, PAMELA DANAGHER, JOSEPH ZIMMERMANN
-
Patent number: 6093563Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.Type: GrantFiled: July 8, 1994Date of Patent: July 25, 2000Assignee: IBEX Technologies R and D, Inc.Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
-
Patent number: 6054569Abstract: The present invention describes a method for the production of two highly purified enzymes capable of degrading chondroitin sulfate polysaccharides. A multi-step purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography, hydroxylapatite chromatography, high resolution ion exchange chromatography and size exclusion is outlined. A 77,000.+-.5,000 Dalton protein capable of degrading chondroitin sulfates A and C and a 55,000.+-.2,300 Dalton protein capable of degrading dermatan sulfate were isolated. The genes encoding these enzymes, chondroitinase AC and chondroitinase B, respectively, have been cloned and methods for their use are described.Type: GrantFiled: September 17, 1997Date of Patent: April 25, 2000Assignee: IBEX Technologies R and D, Inc.Inventors: D. Clark Bennett, Maryse Laliberte, Kangfu Gu, Joseph Zimmermann, Anna Lydia Tkalec, Dominique Fink, Robert Linhardt
-
Patent number: 5997863Abstract: Glycosaminoglycans, including heparinases 1, 2 and 3 as well as chondroitinases AC and B from the Gram negative bacteria Flavobacterium heparinum, can be used either separately or in combination to manipulate cell proliferation. In one embodiment, heparinases are administered to degrade heparan sulfate components of the extracellular matrix, thereby allowing the heparin binding growth factors which are stored in the extracellular matrix to migrate to adjacent cells. The mobility of chemoattractant agents, growth factors and cells also can be increased by treating tissues with glycosaminoglycan degrading enzymes, both chondroitinases and heparinases. The enzymatic removal of chondroitin sulfates from cell surfaces effectively increases the availability of growth factor receptors on the cell's surface. Selectively removing heparan sulfate from cell surfaces while leaving the extracellular matrix intact, conversely, inhibits cell proliferation by down regulating the cell's response to growth factors.Type: GrantFiled: July 8, 1994Date of Patent: December 7, 1999Assignee: Ibex Technologies R and D, Inc.Inventors: Joseph Zimmermann, Israel Vlodavsky, Clark Bennett, Pamela Danagher, Richard Broughton
-
Patent number: 5919693Abstract: The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.Type: GrantFiled: July 25, 1997Date of Patent: July 6, 1999Assignee: IBEX Technologies Corp.Inventors: Hongsheng Su, Francoise Blain, Clark Bennett, Kangfu Gu, Joseph Zimmermann, Roy Musil
-
Patent number: 5681733Abstract: The present invention describes the isolation and sequence of genes from Flavobacterium heparinum encoding heparin and heparan sulfate degrading enzymes, heparinase II and heparinase III (EC 4.2.2.8). It further describes a method of expressing and an expression for heparinases I, II and III using a modified ribosome binding region derived from a promoter from glycosaminoglycan lyase genes of F. heparinum. Also, a multi-step protein purification method incorporating cell disruption, cation exchange chromatography, affinity chromatography and hydroxylapatite chromatography is outlined. Antibodies against a post-translational modification moiety common to Flavobacterium heparinum proteins and a method to obtain antibodies specific to these moieties and to the amino acid sequences of heparinases I, II and III are described.Type: GrantFiled: June 10, 1994Date of Patent: October 28, 1997Assignee: Ibex TechnologiesInventors: Hongsheng Su, Francoise Blain, Clark Bennett, Kangfu Gu, Joseph Zimmermann, Roy Musil
-
Patent number: 4402833Abstract: An environmentally sound system for the removal of elemental phosphorus from waste water resulting from phosphorus manufacture, use, conversion to other products, and storage, wherein the waste water is treated with a material such as lime that produces an insoluble phosphate, filtering the precipitate and passing the filtrate through a column of an adsorbent, such as activated carbon, to produce elemental phosphorus-free water which can be discarded without deleterious effects to the environment.Type: GrantFiled: February 24, 1981Date of Patent: September 6, 1983Assignee: Occidental Chemical CorporationInventors: W. Clark Bennett, Theodore T. Garrett